Guggenheim Starts Coverage on Curis, Inc. (CRIS) Setting A Rating Of “Buy”


Curis, Inc. (NASDAQ:CRIS).

On October 24 analysts at Guggenheim started coverage giving it an initial rating of “Buy”.

The company is so far trading up by 3.12%% since yesterday’s close of 1.57. Shares last traded at $1.62 a tad below $1.71, the stock’s 50 day moving average and which is much lower than the 200 day moving average of $1.91. The 50 day moving average went down $-0.10 or -5.559% and the 200 day average went down by -15.084%.

Curis, Inc., launched on February 14, 2000, is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Business’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes..

As of the last earnings report the EPS was $-0.50 and is projected to be $-0.40 for the current year with 143,878,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.09 and the next full year EPS is projected to be $-0.40.

Short traders are feeling a little more bullish on Curis, Inc. lately as indicated by the motion in short interest. The company recorded a fall in short interest from September 15, 2017 to September 29, 2017 of -7.13%. Short shares fell 165,592 over that period. Days to cover decreased from 3.0 to 2.0 and the percentage of shorted shares was 0.01% on September 29.